



NZX/ASX Announcement

6 May 2026

TruScreen Partners with LSUTH on Gates Foundation Grant Application to Advance Cervical Cancer Screening in Nigeria

TruScreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) is pleased to announce its collaboration with Nigeria's Lagos State University Teaching Hospital (LASUTH) and Lagos State University College of Medicine (LASUCOM) for a Bill & Melinda Gates Foundation (Gates Foundation) grant application focused on cost-disruptive cervical cancer screening in Nigeria.

The application targets the Gates Foundation's Grand Challenges: Innovations in Cost-Disruptive Tools for Diagnosis and Screening (OPP12345) programme. Dr. Ayokunle Moses Olumodeji, Consultant Gynaecological Oncologist at LASUTH, selected TruScreen's AI enabled cervical cancer screening medical device as the cornerstone of his proposed study.

Dr. Olumodeji is the lead investigator for several global health initiatives, including the Gates Foundation-funded AZIN-V Trial and the Grand Challenges Canada CATCH Study, and has previously served as a site investigator for the Bill & Melinda Gates Foundation and Grand Challenges Canada.

About the proposed study

The study aims to identify a cost-effective, easily implemented solution for cervical cancer screening in Nigeria, a country where laboratory infrastructure and trained cytology personnel are limited. Nigeria has the highest number of cervical cancer cases in Africa, reporting 14,089 new cases and 8,240 reported deaths in 2022 (WHO).

Dr. Olumodeji's proposal, centers on the validation of a same-visit "Screen-and-Treat" model that pairs the TruScreen AI-enabled screening medical device with thermal ablation treatment in decentralised rural clinics.

- Funding requested from the Bill & Melinda Gates Foundation: US\$300,000
- Duration: Two years from award.
- Cohort: 500 to 1,500 women, dependent on funding
- Application lodged: 28 April 2026.
- Grant decision: Results expected within six months of submission.

Why TruScreen was selected

Dr. Olumodeji selected TruScreen given its ability to perform in low-resource settings: does not require laboratory facilities or specialist personnel, simple to train and operate, fully portable, delivers real-time results at the point of care. These characteristics align directly with the Gates Foundation's requirement for cost-disruptive, software-defined diagnostics that can be deployed at scale.



Strategic significance

LASUTH works closely with the Nigerian government and serves as an advisor on public health policy, positioning the proposed study to influence national screening guidelines beyond the trial itself. A successful grant award would generate the first West African validation dataset for TruScreen and lay the groundwork for the medical device to be adopted as the standard-of-care for same-visit cervical cancer screening and treatment in Nigeria.

Lagos State University Teaching Hospital is the leading tertiary referral centre in Nigeria and the clinical arm of Lagos State University College of Medicine (LASUCOM). The hospital's Gynaecological Oncology Unit conducts clinical research and policy advisory work in partnership with the Nigerian government and international funders.

Authorised by the Board for filing with the NZX/ASX.

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org

For personal use only



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures

an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.

For personal use only



About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.

DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

For personal use only